In a nutshell This study compared the effectiveness of treatment with all-trans retinoic acid (ATRA; Retin-a) and arsenic trioxide (ATO; Trisenox) to ATRA-ATO with chemotherapy (CHT) in patients with newly diagnosed acute promyelocytic leukemia (APL). The data showed that treatment with ATRA-ATO was equally effective as ATRA-ATO plus CHT in these...
Read MoreType of AML-M3 – Acute promyelocytic leukemia (APL) Posts on Medivizor
How does all-trans retinoic acid and arsenic trioxide treatment affect the long-term quality of life of patients with acute promyelocytic leukemia?
In a nutshell This study assessed the treatment effects of all-trans retinoic acid (ATRA; Vesanoid) and arsenic trioxide (ATO; Trisenox), compared to ATRA with standard chemotherapy on long-term health-related quality of life (HRQoL) in patients with acute promyelocytic leukemia (APL). The data showed better long-term HRQoL measures in patients treated...
Read MoreArsenic trioxide, ATRA and vitamin C as a maintenance treatment in patients with acute promyelocytic leukemia
In a nutshell This study aimed to investigate if arsenic trioxide was safe and effective as a maintenance treatment for patients with acute promyelocytic leukemia. This study concluded that this maintenance treatment was safe and effective in these patients. Some background Acute promyelocytic...
Read MoreTreating patients with high risk acute promyelocytic leukemia (APL) with ATRA, arsenic trioxide and gemtuzumab ozogamicin
In a nutshell The study evaluated the effectiveness and safety of combing all-trans retinoic acid (ATRA; Vesanoid), arsenic trioxide (ATO; Trisenox), and gemtuzumab ozogamicin (GO; Milotarg) in treating patients with high risk (HR) acute promyelocytic leukemia (APL). The authors found that the combination therapy was effective and well...
Read MoreArsenic trioxide and Realgar-Indigo naturalis formula for children with leukemia
In a nutshell This study compared arsenic trioxide (ATO; Trisenox) with the Realgar-Indigo naturalis formula (RIF) in the treatment of children with acute promyelocytic leukemia (APL). Researchers found that oral RIF is as safe and effective as intravenous (IV) ATO in the treatment of these patients. Some background Acute promyelocytic...
Read More